Log in to your Inderes Free account to see all free content on this page.
Genovis
28.5 SEK +9.83%1,674 investors are following this company
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Revenue
158.23M
EBIT %
34.27 %
P/E
30.32
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GENO
Daily low / high price
25.65 / 28.5
SEK
Market cap
1.87B SEK
Turnover
4.44M SEK
Volume
168K
Financial calendar
General meeting
15.05.2024
Interim report
15.05.2024
Interim report
20.08.2024
Interim report
08.11.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Mikael Lönn | 14.5 % | 14.5 % |
State Street Bank And Trust Co, W9 | 8.4 % | 8.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Genovis AB: NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING
Genovis AB: Carthesian Therapeutics terminates Genovis Licence Agreement
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio